Tell us about your biggest client wins this year. Class certification was granted in both In re Loestrin 24 FE Antitrust Litigation and In re Niaspan Antitrust Litigation, which both allege that drug manufacturers unlawfully delayed and impaired generic competition. [The firm] also defeated defendants' motions to dismiss in In re Zetia (Ezetimibe) Antitrust Litigation, another pay-for-delay case alleging that defendants Merck and Glenmark kept generic Zetia off the market, and in In re Generic Pharmaceuticals Pricing Antitrust Litigation, one of the largest [multidistrict litigation] cases in the county, involving allegations of widespread price-fixing among generic drug manufacturers.

What's the best lesson you learned as a young lawyer? The facts matter—a lot.

What's been the most significant change in your practice area, and how have you adjusted? The evolution of courts' approaches to class certification; we adjust by further developing the record at time of certification.

Share an interesting fact about your firm that few know. The writer of the seminal treatise on class actions, "Newberg on Class Actions," started out as a Berger Montague attorney.

Submitted by David Sorensen, Berger Montague managing shareholder.